iBio, Inc. Statistics
Total Valuation
iBio, Inc. has a market cap or net worth of $23.90 million. The enterprise value is $19.50 million.
Important Dates
The next estimated earnings date is Tuesday, November 11, 2025, after market close.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
iBio, Inc. has 20.25 million shares outstanding. The number of shares has increased by 174.05% in one year.
| Current Share Class | 20.25M |
| Shares Outstanding | 20.25M |
| Shares Change (YoY) | +174.05% |
| Shares Change (QoQ) | +45.91% |
| Owned by Insiders (%) | 3.95% |
| Owned by Institutions (%) | 16.47% |
| Float | 19.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 31.76 |
| Forward PS | n/a |
| PB Ratio | 1.57 |
| P/TBV Ratio | 3.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 48.75 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.59, with a Debt / Equity ratio of 0.24.
| Current Ratio | 1.59 |
| Quick Ratio | 1.42 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -87.75 |
Financial Efficiency
Return on equity (ROE) is -101.52% and return on invested capital (ROIC) is -52.14%.
| Return on Equity (ROE) | -101.52% |
| Return on Assets (ROA) | -44.79% |
| Return on Invested Capital (ROIC) | -52.14% |
| Return on Capital Employed (ROCE) | -108.92% |
| Revenue Per Employee | $20,000 |
| Profits Per Employee | -$918,850 |
| Employee Count | 20 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -59.30% in the last 52 weeks. The beta is 0.89, so iBio, Inc.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | -59.30% |
| 50-Day Moving Average | 0.87 |
| 200-Day Moving Average | 1.77 |
| Relative Strength Index (RSI) | 63.35 |
| Average Volume (20 Days) | 6,725,239 |
Short Selling Information
The latest short interest is 412,382, so 2.04% of the outstanding shares have been sold short.
| Short Interest | 412,382 |
| Short Previous Month | 903,899 |
| Short % of Shares Out | 2.04% |
| Short % of Float | 2.15% |
| Short Ratio (days to cover) | 1.23 |
Income Statement
In the last 12 months, iBio, Inc. had revenue of $400,000 and -$18.38 million in losses. Loss per share was -$1.75.
| Revenue | 400,000 |
| Gross Profit | 400,000 |
| Operating Income | -18.60M |
| Pretax Income | -18.38M |
| Net Income | -18.38M |
| EBITDA | -17.83M |
| EBIT | -18.60M |
| Loss Per Share | -$1.75 |
Full Income StatementBalance Sheet
The company has $8.58 million in cash and $3.57 million in debt, giving a net cash position of $5.01 million or $0.25 per share.
| Cash & Cash Equivalents | 8.58M |
| Total Debt | 3.57M |
| Net Cash | 5.01M |
| Net Cash Per Share | $0.25 |
| Equity (Book Value) | 14.88M |
| Book Value Per Share | 0.77 |
| Working Capital | 3.62M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.30 million and capital expenditures -$16,000, giving a free cash flow of -$15.32 million.
| Operating Cash Flow | -15.30M |
| Capital Expenditures | -16,000 |
| Free Cash Flow | -15.32M |
| FCF Per Share | -$0.76 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -4,650.50% |
| Pretax Margin | -4,594.25% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
iBio, Inc. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -174.05% |
| Shareholder Yield | -174.05% |
| Earnings Yield | -74.98% |
| FCF Yield | -62.51% |
Analyst Forecast
The average price target for iBio, Inc. is $4.50, which is 281.36% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.50 |
| Price Target Difference | 281.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 29, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Nov 29, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
iBio, Inc. has an Altman Z-Score of -20.85 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -20.85 |
| Piotroski F-Score | 2 |
